IL2 and systemic lupus erythematosus: An interesting study focusing on the safety and efficacy of low dose IL-2 in 11 autoimmune disease in 46 patients including SLE found significant Treg-expansion without effector T-cell activation (Rosenzwajg et al., 2019).